Pioglitazone time-dependently reduces tumour necrosis factor-α level in muscle and improves metabolic abnormalities in Wistar fatty rats

Diabetologia

Volumn 41, Issue 3, 1998, Pages 257-264

  Murase, K ^a   Odaka, H ^a   Suzuki, M ^a   Tayuki, N ^a   Ikeda, H ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Insulin resistance; Muscle TNF ; Pioglitazone; Sphingomyelinase; Wistar fatty rat

Indexed keywords

LEPTIN; PIOGLITAZONE; SPHINGOMYELIN PHOSPHODIESTERASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; INSULIN BLOOD LEVEL; MUSCLE METABOLISM; NONHUMAN; OBESITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS; DIABETES MELLITUS, EXPERIMENTAL; HYPOGLYCEMIC AGENTS; IMMUNOENZYME TECHNIQUES; INSULIN; INSULIN RESISTANCE; MALE; MUSCLE, SKELETAL; OBESITY; RATS; RATS, MUTANT STRAINS; RATS, WISTAR; SPHINGOMYELIN PHOSPHODIESTERASE; THIAZOLES; THIAZOLIDINEDIONES; TIME FACTORS; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031750246     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250050901     Document Type: Article

References (40)

1. DeFronzo RA, Ferrannini E, Koivisto V (1983) New concepts in the pathogenesis and treatment of noninsulin-dependent diabetes mellitus. Am J Med 74 (Suppl 1 A):52-81
2. Efendic S, Luft R, Wajngot A (1984) Aspects of the pathogenesis of type 2 diabetes. Endocr Rev 5: 395-410
3. Olefsky JM (1985) Pathogenesis of insulin resistance and hyperglycaemia in non-insulin-dependent diabetes mellitus. Am J Med 79 (Suppl 3B):1-7
4. Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259: 87-91
5. Hamann A, Benecke H, Le Marchand-Brustel Y, Susulic VS, Lowell BB, Flier JS (1995) Characterization of insulin resistance and NIDDM in transgenic mice with reduced brown fat. Diabetes 44: 1266-1273
6. Hotamisligil GS, Spiegelman BM (1994) Tumor necrosis factor-α: a key component of the obesity-diabetes link. Diabetes 43: 1271-1278
7. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM (1995) Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 95: 2409-2415
8. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB (1995) The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 95: 2111-2119
9. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM (1994) Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-α. J Clin Invest 94: 1543-1549
10. Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA (1996) The expression of TNF-α by human muscle. Relationship to insulin resistance. J Clin Invest 97: 1111-1116
11. Hofmann C, Lorenz K, Braithwaite SS et al. ( 1994) Altered gene expression for tumor necrosis factor-α and its receptors during drug and dietary modulation of insulin resistance. Endocrinology 134: 264-270
12. Haring HU Mehnert H (1993) Pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: candidates for a signal transmitter defect causing insulin resistance of the skeletal muscle. Diabetologia 36: 176-182
13. Peraldi P, Hotamisligil GS, Buurman WA, White MF, Spiegelman, BM. (1996) Tumor necrosis factor (TNF)-α inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. J Biol Chem 271:13018-13022
14. Liu J, Mathias S, Yang Z, Kolesnick RN (1994) Renaturation and tumor necrosis factor-α stimulation of a 97-kDa ceramide-activated protein kinase. J Biol Chem 269: 3047-3052
15. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. Science 271: 665-668
16. Ikeda H, Taketomi S, Sugiyama Y et al. (1990) Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneim Forsch Drug Res 40: 156-162
17. Ikeda H, Shino A, Matsuo T, Iwatsuka H, Suzuoki Z (1981) A new genetically obese-hyperglycaemic rat (Wistar fatty). Diabetes 30: 1045-1050
18. Sugiyama Y, Taketomi S, Shimura Y, Ikeda H, Fujita T (1990) Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats. Arzneim Forsch Drug Res 40: 263-267
19. Sugiyama Y, Shimura Y, Ikeda H (1990) Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats. Arzneim Forsch Drug Res 40: 436-440
20. Hayakawa T, Shiraki T, Morimoto T, Shii K, Ikeda H (1996) Pioglitazone improves insulin signaling defects in skeletal muscle from Wistar fatty (fa/fa) rats. Biochem Biophysi Res Commun 223: 439-444
21. Murase K, Takeuchi R, Furukawa S, Furukawa Y, Hayashi K (1990) Highly sensitive enzyme immunoassay for β-nerve growth factor (NGF): a tool for measurement of NGF in rat serum. Biochem Int 22: 807-813
22. Gatt S, Dinur T, Barenholz Y (1978) A spectrophotometric method for determination of sphingomyelinase. Biochem Biophys Acta 530: 503-507
23. Poll TVD, Romijn JA, Endert E, Borm JJJ, Buller HR, Sauerwein HP (1991) Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. Am J Physiol 261:E457-E465
24. Pereira BJG, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA (1994) Plasma levels of IL-1b, TNFa and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney International 45: 890-896
25. Zhang B, Berger J, Hu E et al. (1996) Negative regulation of peroxisome proliferator-activated receptor-γ gene expression contributes to the antiadipogenic effects of tumor necrosis factor-α. Mol Endocrinol 10: 1457-1466
26. Hannun YA, Bell RM (1993) The sphingomyelin cycle: a prototypic sphingolipid signaling pathway. Adv Lipid Res 25: 27-41
27. Long SD, Pekala PH (1996) Lipid mediators of insulin resistance: ceramide signalling down-regulates GLUT4 gene transcription in 3T3-L1 adipocytes. Biochem J 319: 179-184
28. Begum N, Ragolia L (1995) Effect of tumor necrosis factor-α on insulin action in cultured rat skeletal muscle cells. Endocrinology 137:2441-2446
29. Begum N, Ragolia L, Srinivasan M (1996) Effect of tumor necrosis factor-α on insulin-stimulated mitogen-activated protein kinase cascade in cultured rat skeletal muscle cells. Eur J Biochem 238: 214-220
30. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptorγ (PPARγ). J Biol Chem 270: 12953-12956
31. Vidal-Puig A, Jimenez-Linan M, Lowell BB et al. (1996) Regulation of PPARγ gene expression by nutrition and obesity in rodents. J Clin Invest 97: 2553-2561
32. Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA (1994) Peroxisome proliferator-activated receptor (PPAR) γ: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 135: 798-800
33. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM (1994) mPPARγ2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8: 1224-1234
34. Frederich RC, Lollmann B, Hamann A et al. (1995) Expression of oh mRNA and its encoded protein in rodents. Impact of nutrition and obesity. J Clin Invest 96: 1658-1663
35. De Vos P, Saladin R, Auwerx J, Staels B (1995) Induction of ob gene expression by corticosteroids is accompanied by body weight loss and reduced food intake. J Biol Chem 270: 15958-15961
36. Zhang B, Graziano MP, Doebber TW et al. (1996) Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. J Biol Chem 16: 9455-9459
37. Sreenan S, Sturis J, Pugh W, Burant CF, Polonsky KS (1996) Prevention of hyperglycaemia in the Zucker diabetic fatty ral by treatment with metformin or troglitazone. Am J Physiol 271:E742-E747
38. Masuda K, Okamoto Y, Tsuura Y et al. (1995) Effects of troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glihenclamide. Diahetologia 38: 24-30
39. Fulgencio JP, Kohl C, Girard J, Pegorier JP (1996) Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats. Diabetes 45: 1556-1562
40. Kellerer M, Kroder G, Tippmer S et al. (1994) Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts. Diabetes 43: 447-453